Liquid embolic market seen reaching $703.6M by 2032

By AI, Created 12:11 PM UTC, May 27, 2026, /AGP/ – Persistence Market Research projects the global liquid embolic market will grow from $384.2 million in 2025 to $703.6 million by 2032, driven by rising use of minimally invasive neurovascular procedures and embolization technologies. North America leads now, while Asia Pacific is emerging as the fastest-growing region.

Why it matters: - Liquid embolic agents are increasingly used to block abnormal blood flow in neurovascular and oncology procedures. - Growing demand for minimally invasive treatment is pushing hospitals and specialists toward embolization over traditional surgery. - The market opportunity is expanding as cases of cerebral aneurysms, vascular disorders and arteriovenous malformations increase worldwide.

What happened: - Persistence Market Research projects the global liquid embolic market will rise from US$ 384.2 million in 2025 to US$ 703.6 million by 2032. - The forecast implies a 9.0% compound annual growth rate over the period. - The report identifies North America as the leading regional market. - The report also points to Asia Pacific as a fast-growing region. - A free sample is available More information.

The details: - Liquid embolic agents are used in minimally invasive procedures to block abnormal blood flow during neurovascular and oncology treatments. - Image-guided surgery and advanced interventional radiology are supporting adoption. - Healthcare providers are using liquid embolic products for procedural precision and faster patient recovery. - The market is segmented by product type, application and end-user. - Product types include ethylene vinyl alcohol copolymer-based agents, cyanoacrylate-based agents and other products. - Ethylene vinyl alcohol copolymer products are preferred for better control and visibility during procedures. - Neurovascular disease is the leading application segment because of treatment demand for aneurysms and arteriovenous malformations. - Oncology applications are gaining traction as embolization becomes more common in tumor treatment. - Hospitals remain the leading end-user segment because they have advanced imaging systems and skilled specialists. - Specialty clinics and ambulatory surgical centers are also adopting embolization more often. - Continuous advances in embolic materials and catheter technologies are expected to support growth.

Between the lines: - The forecast suggests embolization is moving from a specialized option to a broader standard of care in interventional treatment. - North America’s lead reflects stronger healthcare infrastructure, reimbursement systems and adoption of advanced technologies. - The report’s growth case for Asia Pacific is tied to healthcare investment, expanding infrastructure and wider access to minimally invasive care. - High treatment costs, the need for skilled professionals and limited infrastructure in developing markets remain adoption hurdles. - The report names Medtronic, Stryker Corporation, Johnson & Johnson, Terumo Corporation, Penumbra Inc. and Merit Medical Systems as key companies in the market.

What’s next: - Market growth is expected to continue as healthcare systems invest in embolization technologies and related imaging tools. - Wider use in oncology and neurovascular procedures could deepen demand across hospitals and specialty centers. - Emerging economies may create additional upside if access, training and infrastructure improve. - A customization option is available Customize this report. - The full report is available Buy the full report.